Business News • MarketWire • Radient Pharmaceuticals Provides Update Regarding 2010 Form 10K; Anticipated Results & NYSE Amex Hearing |
Radient Pharmaceuticals Provides Update Regarding 2010 Form 10K; Anticipated Results & NYSE Amex Hearing |
|
|
Radient Pharmaceuticals Provides Update Regarding 2010 Form 10K; Anticipated Results & NYSE Amex Hearing
TUSTIN, CA--(Marketwire - April 18, 2011) - Radient Pharmaceuticals Corporation ("RPC") (NYSE Amex: RPC), a US-based company specializing in the research, development, and international commercialization of in vitro diagnostic (IVD) cancer tests, announced today, as disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission ("SEC") on April 14, 2011, that due to requests for financial information from and related to the Company's deconsolidated Chinese subsidiary Jade Pharmaceuticals, Inc. ("JPI"), the Company was not able to complete its audited financial statements for the fiscal year ended December 31, 2010 in a timely manner, and is therefore unable to file its Form 10-K with the SEC by April 15, 2011 as required. JPI indicated they are gathering the requested data and information and RPC expects to receive it shortly. RPC will therefore require additional time t
View More : http://www.marketwire.com/mw/release.do?id=1428775&sourceType=3
|
|
|